Menlo Therapeutics Inc. Contracts & Agreements

First Amendment to the VYNE Therapeutics Inc. 2023 Equity Incentive Plan (Filed With SEC on December 12, 2024)

Non-Employee Director Compensation Policy (Filed With SEC on March 1, 2024)

Sales Agreement, dated as of (Filed With SEC on March 1, 2024)

Form of Employee Restricted Share Unit Grant Notice and Restricted Share Unit Award Agreement under the 2023 Equity Incentive Plan (Filed With SEC on December 13, 2023)

Form of Employee Option Grant Notice and Option Agreement under the 2023 Equity Incentive Plan (Filed With SEC on December 13, 2023)

Form of Director Option Grant Notice and Option Agreement under the 2023 Equity Incentive Plan (Filed With SEC on December 13, 2023)

VYNE Therapeutics Inc. 2023 Equity Incentive Plan (Filed With SEC on December 13, 2023)

Form of Registration Rights Agreement, dated as of October 27, 2023, by and among VYNE Therapeutics Inc. and the Purchasers (Filed With SEC on October 30, 2023)

Form of Securities Purchase Agreement, dated as of October 27, 2023, by and among VYNE Therapeutics Inc. and the Purchasers (Filed With SEC on October 30, 2023)

Form of Pre-Funded Warrant to Purchase Common Stock (Filed With SEC on October 30, 2023)

License Agreement, dated as of April 28, 2023, by and between VYNE Therapeutics Inc. and Tay Therapeutics Limited (Filed With SEC on August 14, 2023)

Letter Agreement, dated as of February 27, 2023, by and between VYNE Therapeutics Inc. and Tay Therapeutics Ltd (Filed With SEC on May 11, 2023)

Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 14, 2023)

Registration Rights Agreement, dated November 11, 2022, between VYNE Therapeutics Inc. and Mutual Fund Series Trust, on behalf of Alpha (Filed With SEC on November 14, 2022)

Securities Purchase Agreement, dated November 11, 2022, between VYNE Therapeutics Inc. and Mutual Fund Series Trust, on behalf of Alpha (Filed With SEC on November 14, 2022)

Letter Agreement, dated as of June 15, 2022, by and between VYNE Therapeutics Inc. and In4Derm Limited (Filed With SEC on August 12, 2022)

Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 17, 2022)

Offer Letter, dated as of March 15, 2022, by and between VYNE Pharmaceuticals Inc. and Tyler Zeronda (Filed With SEC on March 17, 2022)

Offer Letter, dated as of March 7, 2022, by and between VYNE Pharmaceuticals Inc. and Iain Stuart (Filed With SEC on March 17, 2022)

Registration Rights Agreement, dated as of March 15, 2022, by and between the Company and Lincoln Park (Filed With SEC on March 15, 2022)

Purchase Agreement, dated as of March 15, 2022, by and between the Company and Lincoln Park (Filed With SEC on March 15, 2022)

Asset Purchase Agreement, dated as of January 12, 2022, by and between VYNE Therapeutics Inc. and Journey Medical Corporation (Filed With SEC on January 13, 2022)

Evaluation and Option Agreement, dated as of April 30, 2021, by and between In4Derm Limited and VYNE Therapeutics Inc (Filed With SEC on November 10, 2021)

License Agreement (Topical), dated as of August 9, 2021, by and between In4Derm Limited and VYNE Therapeutics Inc (Filed With SEC on November 10, 2021)

Controlled Equity Offering Sales AgreementSM, dated August 12, 2021, by and between VYNE Therapeutics Inc. and Cantor Fitzgerald & Co (Filed With SEC on August 12, 2021)

Offer Letter, dated as of June 7, 2021, by and between Tyler Zeronda and VYNE Pharmaceuticals Inc (Filed With SEC on August 12, 2021)

Offer Letter, dated as of April 7, 2021, by and between Mutya Harsch and VYNE Pharmaceuticals Inc (Filed With SEC on May 6, 2021)

Offer Letter, dated as of April 7, 2021, by and between Andrew Saik and VYNE Pharmaceuticals Inc (Filed With SEC on May 6, 2021)

Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 4, 2021)

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan (Filed With SEC on March 4, 2021)

Form of Securities Purchase Agreement, dated January 26, 2021, among VYNE Therapeutics Inc. and the purchasers identified therein (Filed With SEC on January 28, 2021)

Amendment No. 1 to Amended and Restated Credit Agreement and Guaranty, dated August 5, 2020, by and among Menlo Therapeutics Inc., Foamix Pharmaceuticals Ltd., Foamix... (Filed With SEC on August 6, 2020)

License Agreement, dated as of April 21, 2020, by and between Foamix Pharmaceuticals Ltd. and Cutia Therapeutics (HK) Limited (Filed With SEC on August 6, 2020)

Underwriting Agreement, dated June 4, 2020, among Menlo Therapeutics Inc., Cowen and Company, LLC and Piper Sandler & Co., as representatives of the several underwriters named in... (Filed With SEC on June 9, 2020)

Second Amended and Restated Warrant, by and among Menlo Therapeutics Inc. and Orbimed Royalty & Credit Opportunities III, LP (Filed With SEC on May 11, 2020)

Form of Share Option Grant Notice and Option Agreement under the Menlo Therapeutics Inc. 2019 Equity Incentive Plan for U.S. and Israeli Employees (Filed With SEC on May 11, 2020)

Menlo Therapeutics Inc. 2019 Equity Incentive Plan (Filed With SEC on May 11, 2020)

Amended and Restated Security Agreement, dated as of March 9, 2020, among Foamix Pharmaceuticals Inc., Foamix Pharmaceuticals Ltd., Menlo Therapeutics Inc. and Perceptive Credit... (Filed With SEC on May 11, 2020)

Amended and Restated Credit Agreement and Guaranty, dated as of March 9, 2020, among Foamix Pharmaceuticals Inc., Menlo Therapeutics Inc., Foamix Pharmaceuticals Ltd., the... (Filed With SEC on May 11, 2020)

Second Amended and Restated Warrant, by and among Menlo Therapeutics Inc. and Perceptive Credit Holdings II, LP (Filed With SEC on May 11, 2020)

Offer Letter, dated as of March 20, 2020, by and between Menlo Therapeutics Inc. and Andrew Saik (Filed With SEC on May 11, 2020)

Offer Letter, dated as of March 25, 2020, by and between Menlo Therapeutics Inc. and David Domzalski (Filed With SEC on May 11, 2020)

Menlo Therapeutics Inc. 2019 Employee Share Purchase Plan (Filed With SEC on May 11, 2020)

Form of Restricted Share Unit Grant Notice and Restricted Share Unit Award Agreement under the Menlo Therapeutics Inc. 2019 Equity Incentive Plan for U.S. and Israeli Executives (Filed With SEC on May 11, 2020)

Form of Share Option Grant Notice and Option Agreement under the Menlo Therapeutics Inc. 2019 Equity Incentive Plan for U.S. and Israeli Executives (Filed With SEC on May 11, 2020)

Form of Restricted Share Unit Grant Notice and Restricted Share Unit Award Agreement under the Menlo Therapeutics Inc. 2019 Equity Incentive Plan for U.S. and Israeli Employees (Filed With SEC on May 11, 2020)

Termination of Employment Agreement and Release, dated as of March 22, 2020, by and between Foamix Pharmaceuticals Ltd. and Ilan Hadar (Filed With SEC on May 11, 2020)

Form of Warrant, by and among Menlo Therapeutics Inc. and certain warrant holders of Foamix Pharmaceuticals Ltd (Filed With SEC on March 10, 2020)

Contingent Stock Rights Agreement, dated as of March 9, 2020, by and between Menlo Therapeutics Inc. and American Stock Transfer & Trust Company, LLC (Filed With SEC on March 10, 2020)

Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 3, 2020)

Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, by and among Menlo Therapeutics Inc., Giants Merger Subsidiary Ltd. and Foamix Pharmaceuticals... (Filed With SEC on December 4, 2019)

Form of CSR Agreement (Filed With SEC on November 12, 2019)

Agreement and Plan of Merger, dated as of November 10, 2019, by and among Menlo Therapeutics Inc., Giants Merger Subsidiary Ltd. and Foamix Pharmaceuticals Ltd (Filed With SEC on November 12, 2019)

Form of Foamix Voting Agreement, dated November 10, 2019, by and between Menlo Therapeutics Inc. and certain shareholders of Foamix Pharmaceuticals Ltd (Filed With SEC on November 12, 2019)

Form of Menlo Voting Agreement, dated November 10, 2019, by and between Foamix Pharmaceuticals Ltd. and certain stockholders of Menlo Therapeutics Inc (Filed With SEC on November 12, 2019)

Professional Services Agreement, dated June 1, 2019, by and between the Company and Mary Spellman, M.D (Filed With SEC on August 1, 2019)

First Amendment to Sublease, dated April 12, 2019, by and between the Company and Relypsa, Inc (Filed With SEC on April 24, 2019)

Offer Letter, by and between the Registrant and Mary Spellman, effective as of July 21, 2017 (Filed With SEC on November 7, 2018)

Amendment No. 1 to Offer Letter, by and between the Registrant and Mary Spellman, effective as of April 22, 2018 (Filed With SEC on November 7, 2018)

Amendment No. 1 to Offer Letter, by and between the Company and Steven Basta, effective as of May 3, 2018 (Filed With SEC on May 7, 2018)

Amendment No. 1 to Offer Letter, by and between the Company and Kristine Ball, effective as of May 3, 2018 (Filed With SEC on May 7, 2018)

Amendment No. 1 to Offer Letter, by and between the Company and Paul Kwon, effective as of May 3, 2018 (Filed With SEC on May 7, 2018)

Exclusive License Agreement, dated as of December 20, 2012, by and between the Company and Merck Sharp & Dohme Corp (Filed With SEC on January 18, 2018)

License and Collaboration Agreement, dated as of August 10, 2016, by and among the Company, Torii Pharmaceutical Co. Ltd. and Japan Tobacco, Inc (Filed With SEC on January 18, 2018)

Form of Underwriting Agreement (Filed With SEC on January 12, 2018)

Form of Common Stock Certificate (Filed With SEC on January 12, 2018)

2018 Employee Stock Purchase Plan (Filed With SEC on January 12, 2018)

2018 Omnibus Incentive Plan (Filed With SEC on January 12, 2018)

Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Omnibus Incentive Plan (Filed With SEC on January 12, 2018)

Form of Stock Option Agreement under 2011 Stock Incentive Plan (Filed With SEC on December 28, 2017)

Form of Immediately Exercisable Stock Option Agreement under 2011 Stock Incentive Plan (Filed With SEC on December 28, 2017)

Amendment to 2011 Stock Incentive Plan (Filed With SEC on December 28, 2017)

2011 Stock Incentive Plan, as amended (Filed With SEC on December 28, 2017)

Form of Indemnification Agreement for directors and executive officers to be entered into following the offering (Filed With SEC on December 28, 2017)

Form of Indemnification Agreement entered into between the Company and each of its directors and executive officers (Filed With SEC on December 28, 2017)

Consulting Agreement dated as of March 8, 2016, by and between Tigercat Pharma, Inc., and David Collier (Filed With SEC on December 28, 2017)

Offer Letter, dated as of August 15, 2017 by and between the Company and Kristine Ball (Filed With SEC on December 28, 2017)

Offer Letter, dated as of January 14, 2016 by and between the Company and Paul Kwon (Filed With SEC on December 28, 2017)

Offer Letter, dated as of August 17, 2015 by and between the Company and Steven Basta (Filed With SEC on December 28, 2017)

Sublease, dated September 19, 2017, by and between the Company and Relypsa, Inc (Filed With SEC on December 28, 2017)

License and Collaboration Agreement, dated as of August 10, 2016, by and among the Company, Torii Pharmaceutical Co. Ltd. and Japan Tobacco, Inc (Filed With SEC on December 28, 2017)

Exclusive License Agreement, dated as of December 20, 2012, by and between the Company and Merck Sharp & Dohme Corp (Filed With SEC on December 28, 2017)

Second Amended and Restated Investors Rights Agreement, dated June 28, 2017, by and among the Company and the investors listed therein (Filed With SEC on December 28, 2017)

Category

Industry

Companies

Contracts

Menlo Therapeutics Inc. Contracts & Agreements